Coldstream Capital Management Inc. Sells 244 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Coldstream Capital Management Inc. lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 18.2% during the second quarter, Holdings Channel reports. The fund owned 1,094 shares of the biopharmaceutical company’s stock after selling 244 shares during the period. Coldstream Capital Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $574,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. boosted its position in Regeneron Pharmaceuticals by 1.4% during the second quarter. Charles Schwab Investment Management Inc. now owns 720,273 shares of the biopharmaceutical company’s stock worth $378,143,000 after purchasing an additional 9,938 shares during the period. Tableaux LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $67,725,000. CenterBook Partners LP boosted its holdings in shares of Regeneron Pharmaceuticals by 802.9% during the 2nd quarter. CenterBook Partners LP now owns 51,591 shares of the biopharmaceutical company’s stock worth $27,085,000 after buying an additional 45,877 shares during the period. Mufg Securities Americas Inc. grew its stake in Regeneron Pharmaceuticals by 23.6% in the 2nd quarter. Mufg Securities Americas Inc. now owns 2,301 shares of the biopharmaceutical company’s stock valued at $1,208,000 after buying an additional 439 shares during the last quarter. Finally, AXQ Capital LP raised its holdings in Regeneron Pharmaceuticals by 123.7% in the 2nd quarter. AXQ Capital LP now owns 1,541 shares of the biopharmaceutical company’s stock valued at $809,000 after acquiring an additional 852 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $784.61 on Thursday. The firm has a market cap of $82.46 billion, a PE ratio of 18.79, a price-to-earnings-growth ratio of 2.03 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.72. The stock’s fifty day moving average price is $627.29 and its two-hundred day moving average price is $580.60. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $800.99.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.73 by $2.10. The company had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.Regeneron Pharmaceuticals’s quarterly revenue was up .9% on a year-over-year basis. During the same period in the prior year, the firm posted $12.46 EPS. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Thursday, November 20th will be given a $0.88 dividend. The ex-dividend date is Thursday, November 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s payout ratio is presently 8.43%.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares in the company, valued at $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the sale, the vice president directly owned 4,233 shares in the company, valued at approximately $2,757,503.19. This represents a 9.24% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 7.02% of the company’s stock.

Analyst Ratings Changes

REGN has been the subject of a number of research analyst reports. Guggenheim boosted their price objective on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Citigroup lifted their price target on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Jefferies Financial Group boosted their price target on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a research note on Wednesday, August 27th. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday. Finally, Sanford C. Bernstein lifted their target price on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a report on Wednesday, August 27th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $757.91.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.